Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 2, 2014, Pages 389-398

  Cao, Jun ^a,b   Zhang, Jian ^a,b   Wang, Zhonghua ^a,b   Wang, Biyun ^a,b   Lv, Fangfang ^a,b   Wang, Leiping ^a,b   Hu, Xichun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer; Famitinib; Hypothyroidism; Tyrosine kinase; VEGF; VEGFR 2

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; FAMITINIB; GEMCITABINE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; THYROTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANOREXIA; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL BLEEDING; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RASH; THROMBOCYTOPENIA; THYROID FUNCTION; TOOTH PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTHYROIDISM; INDOLES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PYRROLES; SURVIVAL RATE; THYROTROPIN; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84907598458     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2505-x     Document Type: Article

References (50)

1. Banerjee S, Dowsett M, Ashworth A, Martin LA (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4(9):536-550 (Pubitemid 47351464)
2. Ferrara N (2004) Vascular endothelial growth factor basic science and clinical progress. Endocr Rev 25(4):581-611
3. Seymour L, Dajee D, Bezwoda WR (1993) Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26(3):247-252 (Pubitemid 23304240)
4. Hines SJ, Organ C, Kornstein MJ, Krystal GW (1995) Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 6(6):769-779
5. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239-3247
6. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676
7. Robert NJ, Diéras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor r 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252-1260
8. Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32):4286-4293
9. Miles DW, de Haas SL, Dirix LY et al (2013) Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108(5):1052-1060
10. Van Cutsem E, de Haas S, Kang YK et al (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30(17):2119-2127
11. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascularendothelial growth factor and platelet-derived growth factor receptors: determination of apharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327-337 (Pubitemid 36109749)
12. Wilhelm S, Carter C, Lynch M et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5(10):835-844 (Pubitemid 44480537)
13. Bianchi G, Loibl S, Zamagni C et al (2009) Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 20(7):616-624
14. Moreno-Aspitia A, Morton RF, Hillman DW et al (2009) Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 27(1):11-15
15. Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26(11):1810-1816
16. Crown JP, Diéras V, Staroslawska E et al (2013) Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 31(23):2870-2878
17. Zhu AX, Sahani DV, Duda DG et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27(18):3027-3035
18. Hanrahan EO, Ryan AJ, Mann H et al (2009) Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-3609
19. Murukesh N, Dive C, Jayson GC (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 102(1):8-18
20. Deprimo SE, Bello CL, Smeraglia J et al (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32
21. Beuselinck B, Karadimou A, Lambrechts D et al (2013) Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 108(4):887-900
22. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672-4678
23. Cameron D, Brown J, Dent R et al (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATR ICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 4(10):933-942
24. Van Cutsem E, Jayson G, Dive C et al (2011) Analysis of blood plasma factors in the AVITA phase III randomized study of bevacizumab (bev) with gemcitabine-erlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC) European Multidisciplinary Cancer Congress, 23-27 September 2011 Stockholm, Sweden; (abstract 803)
25. Fan M, Zhang J, Wang Z et al (2014) Phosphorylated VEGFR-2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat 143(1):141-151
26. Rini BI, Schiller JH, Fruehauf JP et al (2011) Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 17(11):3841-3849
27. Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9):763-773
28. Schmidinger M, Vogl UM, Bojic M et al (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117(3):534-544
29. Riesenbeck LM, Bierer S, Hoffmeister I et al (2011) Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 29(6):807-813
30. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R (2012) The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol. 30(5):704-710
31. Zhou A, Zhang W, Chang C et al (2013) Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol 72(5):1043-1053
32. Ross DS (2001) Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol Metab Clin North Am 30(2): 245-264, vii
33. Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
34. Escudier B, Eisen T, Stadler WM, TARGET Study Group et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125-134 (Pubitemid 46089673)
35. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345 (Pubitemid 38944402)
36. Lenz HJ, Van Cutsem E, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24(30):4914-4921 (Pubitemid 46630920)
37. Douillard J, Cassidy J, Jassem J et al (2010) Randomized, open-label, phase III study of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer: efficacy by skin toxicity. J Clin Oncol 28(15 suppl):Abstract 3528
38. Price TJ, Sobrero AF, Wilson G et al (2010) Randomized, open-label, phase III study of panitumumab with FOLFIRI versus FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: Efficacy by skin toxicity. J Clin Oncol 28(15 suppl): Abstract 3529
39. Soulieres D, Senzer N, Vokes E, Hidalgo M, Agarwala SS, Siu L (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin 22(1):77-85 (Pubitemid 41095117)
40. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21-28
41. Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22(16):3238-3247 (Pubitemid 41103678)
42. Rini BI, Tamaskar I, Shaheen P et al (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99(1):81-83
43. Tamaskar I, Bukowski R, Elson P et al (2008) Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19(2):265-268 (Pubitemid 351201706)
44. Shinohara N, Takahashi M, Kamishima T et al (2011) The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer 104(2):241-247
45. Wolter P, Stefan C, Decallonne B et al (2008) The clinical implications of sunitinib-induced hypothyroidism:a prospective evaluation. Br J Cancer 99(3):448-454
46. Makita N, Iiri T (2013) Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid. 23(2):151-159
47. Aparicio-Gallego G, Blanco M, Figueroa A et al (2011) New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther 10(12):2215-2223
48. Foekens JA, Peters HA, Grebenchtchikov N et al (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61(14):5407-5414 (Pubitemid 32694919)
49. Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA (2003) Combined vascular endothelial growth factor and TP53 status predicts poor response totamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 9(4):1253-1258 (Pubitemid 36418374)
50. Jayson GC, de Haas S, Delmar P et al (2011) Evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab. European Multidisciplinary Cancer Congress, 23-27 September 2011 Stockholm, Sweden; (abstract 804)